Assyro AI

Orange Book product · Brand (NDA)

SERNIVO

BETAMETHASONE DIPROPIONATE

Brand (NDA)NDA 208079RX PRIMUS PHARMS

At a glance

Feb 05, 2016

Approved

Brand (NDA)

Application

Not listed

TE code

7

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Feb 05, 2016

    10 yr 6 mo ago

  2. Today

  3. Patent 10179137 expires

    Listed drug product patent expiration.

    Aug 31, 2030

    in 4 yr 3 mo

  4. Patent 9364485 expires

    Listed drug product patent expiration.

    Aug 31, 2030

    in 4 yr 3 mo

  5. Patent 9433630 expires

    Listed drug product patent expiration.

    Aug 31, 2030

    in 4 yr 3 mo

  6. Patent 9439911 expires

    Listed drug product patent expiration.

    Aug 31, 2030

    in 4 yr 3 mo

  7. Patent 9655907 expires

    Listed drug product patent expiration.

    Aug 31, 2030

    in 4 yr 3 mo

  8. Patent 9775851 expires

    Listed drug product patent expiration.

    Aug 31, 2030

    in 4 yr 3 mo

  9. Patent 9877974 expires

    Listed drug product patent expiration.

    Aug 31, 2030

    in 4 yr 3 mo

Pharmaceutical detail

Active ingredient

BETAMETHASONE DIPROPIONATE

Strength

EQ 0.05% BASE/SPRAY

Dosage form

SPRAY

Route

TOPICAL

TE code

Not listed

Application

NDA 208079

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (7)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10179137Aug 31, 2030in 4 yr 3 mo
ProductU-1858
9364485Aug 31, 2030in 4 yr 3 mo
ProductU-1858
9433630Aug 31, 2030in 4 yr 3 mo
ProductU-1858
9439911Aug 31, 2030in 4 yr 3 mo
ProductU-1858
9655907Aug 31, 2030in 4 yr 3 mo
ProductU-1858
9775851Aug 31, 2030in 4 yr 3 mo
ProductU-1858
9877974Aug 31, 2030in 4 yr 3 mo
ProductU-1858
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.